ALK and non-small cell lung carcinoma: Crizotinib is a first-generation oral TKI and the first TKI approved for treating ALK-positive NSCLC, effectively inhibits ALK rearrangements, ROS1 rearrangements, high-level MET amplification, and METex14 skipping mutations.